FDA-Approved and Off-Label Uses of Amantadine
Amantadine has three FDA-approved indications: prophylaxis and treatment of influenza A virus infection, treatment of Parkinson's disease/parkinsonism, and treatment of drug-induced extrapyramidal reactions 1.
FDA-Approved Uses
Influenza A Virus
Prophylaxis:
- Chemoprophylaxis against influenza A virus infection (not influenza B)
- 70-90% effective in preventing illness when taken throughout the epidemic period 2, 3
- Can be used as a bridge during the 2-4 week period after vaccination to allow antibody development 1
- Particularly indicated for high-risk patients vaccinated after influenza A activity has begun in the community 2, 4
Treatment:
- Reduces duration and severity of uncomplicated influenza A illness when started within 48 hours of symptom onset 2, 5
- Treatment duration should be 3-5 days or within 24-48 hours after symptom resolution to minimize resistance development 2
- Critical caveat: No evidence that amantadine prevents serious influenza complications like pneumonitis in high-risk patients 1, 5
Important limitation: Due to widespread resistance, amantadine is rarely used for influenza in current practice, though it remains FDA-approved for this indication.
Parkinson's Disease and Parkinsonism
Amantadine is FDA-approved for:
- Idiopathic Parkinson's disease (Paralysis Agitans)
- Postencephalitic parkinsonism
- Symptomatic parkinsonism following carbon monoxide intoxication
- Parkinsonism in elderly patients with cerebral arteriosclerosis 1
Note: Amantadine is less effective than levodopa for Parkinson's disease 1.
Drug-Induced Extrapyramidal Reactions
FDA-approved for treatment of extrapyramidal reactions caused by medications, with lower incidence of anticholinergic side effects compared to traditional anticholinergic antiparkinson drugs 1.
Off-Label Uses (Supported by Research Evidence)
Levodopa-Induced Dyskinesia in Parkinson's Disease
This is the most robustly supported off-label use with high-quality recent evidence:
- Amantadine extended-release (Gocovri®) received FDA approval in 2017 specifically for dyskinesia and later for OFF episodes, representing evolution from off-label to approved use 6, 7
- Pooled phase III trials showed 10.1-point improvement on Unified Dyskinesia Rating Scale versus placebo (p<0.0001) 8
- Reduces OFF time by 1.00 hour/day compared to placebo (p=0.0006) 8
- Benefits appear within 2 weeks and are sustained long-term 6, 8
- Particularly effective in patients meeting 5-2-1 criteria (≥5 levodopa doses/day, ≥2h OFF/day, ≥1h dyskinesia/day) with 2.9 hour/day improvement in "good ON" time 7
Traumatic Brain Injury (TBI)
- Used to improve arousal and cognitive function in patients with disorders of consciousness following TBI 9
- Several clinical practice guidelines recommend amantadine for TBI 9
- Available as IV infusion for unconscious patients, allowing immediate CNS delivery 9
- Evidence supports both neuroprotective and neuroactivating effects 9
Acute Stroke (Non-Traumatic Brain Injury)
- Increasingly prescribed as neurostimulant to promote wakefulness in neurocritical care stroke patients 10, 11
- Used in ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage 11, 10
- Evidence is limited and primarily observational - prospective trials are needed 12, 10
- Typical dosing: 100mg once or twice daily, continued for median 105 days post-rehabilitation admission 11
- Better response associated with higher baseline Glasgow Coma Scale (median 12 vs 9 for nonresponders) 10
- Phase IIb proof-of-concept trial (ANNES study) is ongoing for persisting coma in non-traumatic neurointensive patients 12
Other Movement Disorders (Weak Evidence)
The following lack strong evidence base but are occasionally used 13:
- Huntington's disease
- Tardive dyskinesia
- Atypical parkinsonism
- Drug-induced parkinsonism (beyond extrapyramidal reactions)
Key Dosing Considerations Across All Uses
Age-based adjustments:
- Children 1-9 years: 5 mg/kg/day (max 150 mg/day) 2, 4
- Adults 13-64 years: 100 mg twice daily 2, 4
- Elderly ≥65 years: Maximum 100 mg/day due to declining renal function 4, 14
Renal impairment:
- Dose reduction required for creatinine clearance <50 mL/min 14, 15
- Hemodialysis contributes minimally to clearance 15
Common Pitfalls and Safety Concerns
Central nervous system effects:
- 5-10% experience minor CNS effects (nervousness, anxiety, insomnia, difficulty concentrating) 5
- More serious effects (seizures, confusion) primarily in elderly, those with renal disease, or seizure disorders 5
- Hallucinations are common, particularly with extended-release formulations 8
Other adverse effects:
- Peripheral edema and falls (particularly with ER formulation) 7, 8
- Orthostatic hypotension 8
- Livedo reticularis (cosmetic, reversible)
Resistance development:
- Amantadine-resistant influenza viruses can emerge during treatment 5
- Discontinue as soon as clinically warranted (3-5 days) to minimize resistance 2
Drug interactions:
- Monitor closely in immunodeficient patients, especially those with HIV on multiple medications 5